Is Clene Inc. (CLNN) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 33.0% / 30% | 19.3% / 30% | 0.6% / 30% | 252.92% / 5% | ✗ NOT HALAL |
| DJIM | 33.0% / 33% | 19.3% / 33% | 0.6% / 33% | 252.92% / 5% | ✗ NOT HALAL |
| MSCI | 76.2% / 33% | 44.5% / 33% | 1.4% / 33% | 252.92% / 5% | ✗ NOT HALAL |
| S&P | 33.0% / 33% | 19.3% / 33% | 0.6% / 33% | 252.92% / 5% | ✗ NOT HALAL |
| FTSE | 76.2% / 33% | 44.5% / 33% | 1.4% / 50% | 252.92% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 78.5% | |
| Operating Margin | -9733.8% | |
| Net Margin | 0.0% | |
| Return on Assets (ROA) | -63.5% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$19M |
| Free Cash Flow | -$19M |
| Total Debt | $22M |
| Current Ratio | 0.8 |
| Total Assets | $18M |
Price & Trading
| Last Close | $5.39 |
| 50-Day MA | $5.02 |
| 200-Day MA | $5.96 |
| Avg Volume | 90K |
| Beta | 0.6 |
|
52-Week Range
$2.28
| |
About Clene Inc. (CLNN)
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. It develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, the company markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. Clene Inc. is headquartered in Salt Lake City, Utah.
Related Halal Stocks in Consumer Defensive
Frequently Asked Questions
Is Clene Inc. (CLNN) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Clene Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Clene Inc.'s debt ratio?
Clene Inc.'s debt ratio is 33.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 76.2%.
What are Clene Inc.'s key financial metrics?
Clene Inc. has a market capitalization of $55M, and revenue of $200,000.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.